April 2016

Pride in Progress

Allen C. Ho, MD, and Robert L. Avery, MD

News

News Feature: Protocol T Year 2: What Doctors Are Saying

Two-year results from the DRCR.net's Protocol T trial were released at the end of February. How have retina specialists reacted?

the Editors of Retina Today

Protocol T Year 2: What Doctors Are Saying

Two-year results from the DRCR.net's Protocol T trial were released at the end of February. How have retina specialists reacted?

the editors of Retina Today

Medical Update

Down, But Not Out: How the AAO Has Responded to Medicare's 2016 Retina Fee Cuts

Faced with cuts to retinal detachment reimbursements, the AAO sprang into action.

George A. Williams, MD

Understanding Blue Light

Exposure to certain wavelengths of blue light carries potential blinding effects and a link to AMD.

Aron Shapiro

The Future of Retina: Emerging Technologies and Unmet Needs

Meant to be a forum for new ideas and surgical innovations, the 2016 Vail Vitrectomy meeting did not disappoint. Experts from around the globe shared their expertise and, more so, their thoughts on the future of retina and where it still needs to improve.

M. Ali Khan, MD

Physician Supervision Conundrums

Making sense of “incident to” services and diagnostic tests.

Riva Lee Asbell

A Novel IOL Rescue Technique

The technique preserves the existing IOL and avoids potential complications.

Sumit P. Shah, MD, and Nicholas D. Chinskey, MD

Navigated Microsecond Laser for Recurrent CSCR With Subfoveal Leaks

In a case report, one laser session resolved fluid and improved visual function.

Rohit Yogi, MD; Mahima Jhingan, MD; and Jay Chhablani, MD

A Postmodern View of Anti-VEGF Treatment

Knowledge is power in treating patients with DME.

Nancy M. Holekamp, MD

Uveal Melanoma in an African American Patient

A young woman with no acknowledged white non-Hispanic ancestry received a rare diagnosis.

Kareem Sioufi, MD; Renelle Pointdujour-Lim, MD; and Carol L. Shields, MD

Get the Most Out of Your SD-OCT Device

A review of the features and functions of the Spectralis.

S.K. Steven Houston III, MD

Informed Consent and the Physician-Patient Relationship

Moving from the informative to the deliberative model.

Arun Patel, MD, and Mya Aung, MBS, DO, MMed, Sc(Ophth)

A Primer on Cellular Therapy

The treatment approach has taken aim at its first retinal disease: CMV retinitis.

Mrinali Gupta, MD, and Szilá,rd Kiss, MD

Breakthrough Treatment Modalities for Hereditary Retinal Diseases

Options for managing patients with inherited retinal diseases are becoming more proactive.

Hershel R. Patel, MS, MD, and David Eichenbaum, MD

Will a New Low-Cost Option Join the Anti-VEGF Fold?

An existing cancer drug could offer an alternative treatment to patients with macular diseases.

Brian C. Joondeph, MD, MPS

Gene Therapy on the Horizon for X-Linked Retinoschisis and X-Linked RP

Insights gained from ongoing clinical programs will help guide future studies.

David G. Birch, PhD

5Q With David R.P. Almeida, MD, MBA, PhD

David R.P. Almeida, MD, MBA, PhD, is a vitreoretinal surgeon at VitreoRetinal Surgery, PA, in Minneapolis, Minn.